Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003

Exclusion Criteria

• •1. Presence of an unstable, clinically significant medical condition other than PSP including, but not limited to: hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal, immunological, psychological or neurological disease or malignancy.
• •2. Contraindication to undergoing a lumbar puncture (LP).
• •3. Recent drug or alcohol abuse as defined in Diagnostic and Statistical Manual of Mental Disorders (4th Edition).
• •4. Treatment with any investigational drugs (including placebo) other than BIIB092 or placebo given in Study CN002003 or devices within 90 days prior to enrollment
• •5. Any vaccination within 30 days prior to study drug administration.
• •6. Contraindication to the MRI examination for any reason
• •7. Any other sound medical, psychiatric, and/or social reason as determined by the investigator
• •8. Known history of human immunodeficiency virus.
• •9. Evidence of organ dysfunction or significant deterioration from prior values in CN002003 beyond what is consistent with the target population or that would place the patient at increased risk or risk of early study discontinuation.
• •10. Inability to be venipunctured and/or tolerate venous access.
• •11. History of allergy, hypersensitivity, or serious adverse reaction to monoclonal antibodies or related compounds or allergy to any of the components of the study drug